The Role of the CD40 Pathway in Alloantigen-Induced Hyporesponsiveness In Vivo
Masanori Niimi(John Radcliffe Hospital), Kathryn J. Wood(University of Oxford), Thomas C. Pearson(Emory Healthcare), Raif S. Geha(Boston Children's Hospital), Christian P. Larsen(Emory University Hospital), Peter S. Linsley(Rosetta Stone (United States)), Alejandro Aruffo(University of Washington Medical Center), Kim Campbell, Elaine Thomas(Research & Development Corporation), Peter J. Morris(Menzies School of Health Research), William C. Fanslow(Laboratoire d'Innovation Thérapeutique), Diane Z. Alexander(Emory University), Diane Hollenbaugh(Neoleukin Therapeutics (United States))
Cited by 79
Related Papers
CTLA-4 is a second receptor for the B cell activation antigen B7.
|The Journal of Experimental Medicine|1991|1.7k
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
|Nature|1996|1.5k
The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM
|Nature|1998|942
The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome
|Cell|1993|824
4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses
|The Journal of Experimental Medicine|1997|802